Literature DB >> 20134301

ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy.

.   

Abstract

High unintended pregnancy rates in the United States may in part be the result of relatively low use of long-acting reversible contraceptive (LARC) methods, specifically the contraceptive implant and intrauterine devices. Top-tier reversible methods share the characteristic of requiring a single act of motivation for long-term use, eliminating adherence and user-dependence from the effectiveness equation. According to the World Health Organization's evidence-based Medical Eligibility Criteria for contraceptive use, LARC methods have few contraindications, and almost all women are eligible for implants and intrauterine devices. Because of these advantages and the potential to reduce unintended pregnancy rates, LARC methods should be offered as first-line contraceptive methods and encouraged as options for most women. To increase use of LARC methods, barriers such as lack of health care provider knowledge or skills, low patient awareness, and high upfront costs must be addressed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20134301     DOI: 10.1097/AOG.0b013e3181c6f965

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  55 in total

1.  The impact of out-of-pocket expense on IUD utilization among women with private insurance.

Authors:  Aileen M Gariepy; Erica J Simon; Divya A Patel; Mitchell D Creinin; Eleanor B Schwarz
Journal:  Contraception       Date:  2011-08-17       Impact factor: 3.375

2.  Evidence-based selection of candidates for the levonorgestrel intrauterine device (IUD).

Authors:  Lisa S Callegari; Blair G Darney; Emily M Godfrey; Olivia Sementi; Rebecca Dunsmoor-Su; Sarah W Prager
Journal:  J Am Board Fam Med       Date:  2014 Jan-Feb       Impact factor: 2.657

Review 3.  Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.

Authors:  Mishka Terplan; Dennis J Hand; Melissa Hutchinson; Elizabeth Salisbury-Afshar; Sarah H Heil
Journal:  Prev Med       Date:  2015-04-18       Impact factor: 4.018

4.  Changes in US health care provider attitudes related to contraceptive safety before and after the release of National Guidance.

Authors:  Lauren B Zapata; Isabel A Morgan; Kathryn M Curtis; Suzanne G Folger; Maura K Whiteman
Journal:  Contraception       Date:  2019-07-29       Impact factor: 3.375

5.  Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.

Authors:  Danielle S Grunloh; Teya Casner; Gina M Secura; Jeffrey F Peipert; Tessa Madden
Journal:  Obstet Gynecol       Date:  2013-12       Impact factor: 7.661

6.  Postpartum contraceptive use among women with a recent preterm birth.

Authors:  Cheryl L Robbins; Sherry L Farr; Lauren B Zapata; Denise V D'Angelo; William M Callaghan
Journal:  Am J Obstet Gynecol       Date:  2015-05-21       Impact factor: 8.661

7.  Multi-city assessment of lifetime pregnancy involvement among street youth, Ukraine.

Authors:  Lauren B Zapata; Dmitry M Kissin; Cheryl L Robbins; Erin Finnerty; Halyna Skipalska; Roman V Yorick; Denise J Jamieson; Polly A Marchbanks; Susan D Hillis
Journal:  J Urban Health       Date:  2011-08       Impact factor: 3.671

8.  Urban-Rural Differences in Tubal Ligation Incidence in the State of Georgia, USA.

Authors:  Curtis D Travers; Jessica B Spencer; Carrie A Cwiak; Ann C Mertens; Penelope P Howards
Journal:  J Rural Health       Date:  2017-07-21       Impact factor: 4.333

9.  The Use of ACOG Guidelines: Perceived Contraindications to IUD and Implant Use Among Family Planning Providers.

Authors:  Ash E Philliber; Heather Hirsch; Claire D Brindis; Rita Turner; Susan Philliber
Journal:  Matern Child Health J       Date:  2017-09

Review 10.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.